Potential mechanisms of GLP-1 RAs and SGLT-2 inhibitors for NAFLD and HF are explained by weight reduction, improvement of insulin resistance, reduction of metabolic dysfunction, improvement of lipotoxic effects, and inflammation [51, 52]. The gene discussed is GLP1R; the disease is Insulin resistance.